Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).

Abstract

Paclitaxel, an anti-microtubule agent, is an effective chemotherapeutic drug in breast cancer. Nonetheless, resistance to paclitaxel remains a major clinical challenge. The need to better understand the resistant phenotype and to find biomarkers that could predict tumor response to paclitaxel is evident. In estrogen receptor α-positive (ER(+)) breast cancer… (More)
DOI: 10.1074/jbc.M111.304022

Topics

Cite this paper

@article{Shajahan2012TyrosinephosphorylatedC, title={Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).}, author={Ayesha N. Shajahan and Zachary C. Dobbin and Francis E. Hickman and Sivanesan Dakshanamurthy and Robert Clarke}, journal={The Journal of biological chemistry}, year={2012}, volume={287 21}, pages={17682-92} }